Scios

United States Joins Suits Against Scios and Johnson & Johnson

Pharmaceutical Companies Allegedly Marketed the Drug Natrecor for a Use Not Approved By the Food and Drug Administration WASHINGTON, Feb. 19 /PRNewswire-USNewswire/ -- The United States has intervened in two whistleblower suits filed in the Northern District of California against the d...

Jane Moffitt, J.D., LL.M. Named Vice President of Regulatory Affairs of Nile Therapeutics

...unction and was the head of the regulatory affairs function. Ms. Moffitt also served as President, Treasurer and a member of the Board of Directors of scios R&D, Inc. and BRP, Inc. Ms Moffitt holds a B.S. in Biology and Political Science from Dickinson College, a J.D. from Dickinson School of Law and a L...

ARCA Discovery Changes Name to ARCA biopharma to Reflect Focus on Drug Commercialization

...yed a pivotal role in the successful launch and commercialization of Natrecor, a recombinant form of BNP for acute heart failure. During his tenure at scios he created and built a sales organization from the bottom up. "At this critical juncture, we welcome Randy as an important addition to our team as w...

New Survey Suggests Confusion, Lack of Awareness About Heart Failure Could Be Preventing Critical Early Detection and Treatment

... to drive early detection and treatment of the pervasive condition, and to advance disease prevention. Fight Against Heart Failure(SM) is sponsored by scios Inc., which has provided educational grants to AAHFN, PCNA and SCPC to conduct this program. According to the survey: -- Less than half of U.S...

Study Supports Controversial Heart Failure Drug

...e," Witteles said. Critics quickly put the pressure on the drug's maker, scios Inc., to initiate a large, prospective randomized controlled trial. Such a ...zers hope to gather 7,000 patients. The Stanford study -- also funded by scios -- was much smaller and was conceived before the controversy broke, Wittele...

Manufacturer to Pay $20 Million for Improperly Promoting a Sleep Disorder Drug

... Although the FDA has approved Natrecor's sale to people with congestive heart failure who have trouble breathing while doing minimal activity, scios has been accused of improperly promoting frequent injections of the drug in out-patient settings. South San Francisco-based Genentech also has...

New FDA Approved Drug NATRECOR For Heart Failure Patients

...cor dose. Studies showed patients could breathe better as blood circulation and lung congestion improved with Natrecor treatment. California-based scios Pharmaceuticals said it will start shipping Natrecor to hospitals this week and each vial, a day's treatment, will cost $380. ...

Scios in Medical Technology

Scios Announces Results From Exploratory Nesiritide Study Providing Important New Renal and Mortality Safety Data with a Neutral Effect on the Primary Endpoint

...f. and NEW ORLEANS, March 25, 2007 /PRNewswire/ -- scios Inc. announced today that an exploratory, 920-pati...ific Session in New Orleans (presentation #402-9). scios also announced that it plans to submit the safety ... . See Important Safety Information below. About scios Inc. ...

Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery

...nical development program led by J&JPRD and Bayer HealthCare. Upon regulatory approval, rivaroxaban will be commercialized in the United States by scios Inc. and Ortho-McNeil, Inc. Bayer Schering Pharma will market rivaroxaban throughout the rest of the world. The companies plan to submit regulatory ...

Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery

...ical development program between Bayer HealthCare and J&JPRD. Upon regulatory approval, rivaroxaban will be commercialized in the United States by scios Inc. and Ortho-McNeil, Inc. Bayer Schering Pharma will market rivaroxaban throughout the rest of the world. The companies plan to submit regulatory ...

Scios in Biological Technology

Jennerex Appoints Samantha Miller as Vice President of Corporate Development

.... Miller has held senior positions in business development, including the title of Vice President, in various companies including Anesiva, Theravance, scios Pharmaceuticals, Onyx Pharmaceuticals and Procter & Gamble Pharmaceuticals. "Samantha is an outstanding addition to our executive managemen...

Nuvelo and ARCA biopharma Announce Merger Agreement Creating Late-Stage Cardiovascular Biotechnology Company

...ed Leadership Capable of Driving Value -- Chief Executive Officer: Richard B. Brewer, current president and CEO of ARCA, former president and CEO of scios and senior vice president of sales and marketing of Genentech; -- Chief Science and Medical Officer: Michael R. Bristow, MD, PhD, current chairman a...